Charley brings 30 years of experience in operational finance leadership, financial planning and strategy development, and general management of G&A functions with decades of life science executive roles and strategy consulting. Charley joined Ovid in 2024 as Senior Vice President of Finance and Financial Planning. Prior to Ovid, Charley was CFO of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) where he prepared the company for a complex de-SPAC transaction and helped launch CERo as a public company. Before CERo, Charley held CFO roles at iCAD, Inc. (NASDAQ:ICAD), GI Dynamics, Inc. (ASX:GID), multiple private life science companies, and as consulting CFO/head of finance for various life science clients. Charley’s initial biotech finance position was with Transkaryotic Therapies, Inc. (NASDAQ:TKTX) where he was head of financial planning and analysis during the $1.8 billion acquisition by Shire Pharmaceuticals, Plc. (NASDAQ:SHPG). Prior to TKT, Charley was a strategy consulting partner with Mercer Management Consulting after starting his career working as a scientist in the field of molecular virology. Charley earned a bachelor’s degree in Biology from Colgate University and master’s degrees in Molecular Genetics and Business Administration from The University of Chicago.